drugset / Trial / NCT04634110
Brigatinib Before Brain Irradiation Trial (B3i Trial)
Phase 2
Terminated
1 enrolled
University of Colorado, Denver
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm phase II study of brigatinib alone for patients with brain metastases from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), who have either not been treated previously with a tyrosine kinase inhibitor (TKI) targeting ALK or who have had prior exposure to crizotinib.
Timeline
- Start
- 2020-11-17
- Primary completion
- 2022-04-14
- Completion
- 2022-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brigatinib | Small molecule | 180 mg | — |